In a cohort of 992 breast cancers, Polak et al. [35] demonstrated the majority of tumours highly enriched for Signature 3 did not carry inactivating BRCA1/2 variants but identified PALB2 variants and inactivation of RAD51C as alternative lesions associated with this signature’s activity. Here, PALB2 is linked to breast carcinoma.